Acadia Pharmaceuticals ACAD reported fourth-quarter 2024 earnings of 17 cents per share, missing the Zacks Consensus Estimate ...

Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Hello, and welcome to the Acadia Healthcare fourth quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024 Highlights Adjusted income ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full ... at our inaugural R&D Day in June.” ...

SAN DIEGO — SAN DIEGO — Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported fourth-quarter net income of $143.7 million. The San Diego-based company said it had net income of 86 cents per ...

2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a strong ...

These non-GAAP financial measures include, and are defined, as follows: • EBITDA: net income attributable to Acadia Healthcare ... beginning in the first quarter of 2022 have concluded.

Acadia Pharmaceuticals ACAD reported fourth-quarter 2024 earnings of 17 cents ... Zacks Investment Research Research and development (R&D) expenses were $100.7 million, up 51% year over year.

EBITDA: net income attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for income taxes, net interest expense and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...